Evaluation of (S)-T1 and (S)-T2 ligands targeting α3β4 nAChR as potential nicotine addiction pharmacotherapy
Psychopharmacology · 2024
DOI: 10.1007/s00213-024-06675-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychopharmacology, 2024. Verfasst von Saranda Nianpanich und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand. Hauptthemen laut MEDLINE: Tobacco Use Disorder, Receptors, Nicotinic, Mice, Inbred C57BL, Dopamine. Die Arbeit nennt 57 Literaturangaben.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
OBJECTIVES: Substance use disorders (SUDs) represent a significant global health concern, demanding the development of effective pharmacological treatments. To address this, an investigation was conducted to examine the anti-addictive properties of two compounds, (S)-T1 and (S)-T2, which specifically target the α3β4 nicotinic acetylcholine receptor (nAChR). METHODS: The effects of (S)-T1 and (S)-T2 on nicotine-induced conditioned place preference (CPP), locomotor activity and dopamine levels in particular brain regions associated to addiction were investigated and compared in male C57BL/6N mice. RESULTS: The results demonstrate that neither (S)-T1 nor (S)-T2 induced place conditioning or conditioned place aversion (CPA), suggesting the absence of rewarding or aversive effects. Both compounds significantly attenuated nicotine-induced CPP, with (S)-T1 exhibiting a dose-dependent effect. Furthermore, the co-administration of (S)-T2 (10 mg/kg) with nicotine markedly reduced locomotor activity compared to nicotine treatment alone. Additionally, dopamine analysis revealed that nicotine increased dopamine levels in the nucleus accumbens (NAc) and dorsal striatum, whereas the co-administration of (S)-T1 (1, 3, and 10 mg/kg) and (S)-T2 (10 mg/kg) significantly decreased dopamine levels in these brain regions. No significant effects were observed in the prefrontal cortex (PFC). CONCLUSIONS: These findings suggest that (S)-T1 and (S)-T2 hold promise for treating nicotine addiction by attenuating nicotine-induced CPP and modulating dopamine release in key reward-related brain regions. Further research is needed to gain insights into the underlying mechanisms behind their anti-addictive effects and substantiate their potential for treating nicotine addiction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand.
- Preclinical Toxicity and Efficacy Assessment of Medicines and Chemicals Research Unit, Chulalongkorn University, Bangkok, 10330, Thailand.
- Department of Clinical and Community Pharmacy, Faculty of Pharmacy, University of Surabaya, Surabaya, 60293, Indonesia.
- Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand.
- Pharmaceutical Research Instrument Center, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand.
- Molecular Probes for Imaging Research Network, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand.
Zitieren
APA
Nianpanich, S., Rodsiri, R., Islamie, R., Limpikirati, P., Thanusuwannasak, T., Vajragupta, O., Kanasuwan, A., & Sarasamkan, J. (2024). Evaluation of (S)-T1 and (S)-T2 ligands targeting α3β4 nAChR as potential nicotine addiction pharmacotherapy. Psychopharmacology. https://doi.org/10.1007/s00213-024-06675-w
Vancouver
Nianpanich S, Rodsiri R, Islamie R, Limpikirati P, Thanusuwannasak T, Vajragupta O, et al. Evaluation of (S)-T1 and (S)-T2 ligands targeting α3β4 nAChR as potential nicotine addiction pharmacotherapy. Psychopharmacology. 2024. doi:10.1007/s00213-024-06675-w
BibTeX
@article{Nianpanich2024,
author = {Nianpanich, Saranda and Rodsiri, Ratchanee and Islamie, Ridho and Limpikirati, Patanachai and Thanusuwannasak, Thanundorn and Vajragupta, Opa and Kanasuwan, Apinan and Sarasamkan, Jiradanai},
title = {Evaluation of (S)-T1 and (S)-T2 ligands targeting α3β4 nAChR as potential nicotine addiction pharmacotherapy},
journal = {Psychopharmacology},
year = {2024},
doi = {10.1007/s00213-024-06675-w}
}
EUVIMED